FoundationOne®CDx (F1CDx) is a laboratory test designed to detect genetic mutations in 324 genes and two genomic signatures in tumor tissue. F1CDx is a companion diagnostic that was originally approved for the detection of genetic mutations in patients who may be eligible for treatment with one of fifteen FDA-approved therapies for non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, and ovarian cancer. This approval expands the indications for use of the F1CDx test to include breast cancer patients with certain genetic mutations in the PIK3CA gene. Identifying these changes will help breast cancer patients get personalized treatment with PIQRAY® (alpelisib), a drug used to treat patients with breast cancer.
No hay comentarios:
Publicar un comentario